Summary of the 2017 thyroid radiofrequency ablation guideline and comparison with the 2012 guideline

Ji-Hoon Kim; Jung Hwan Baek; Hyun Kyung Lim; Dong Gyu Na

doi:10.14366/usg.18044

Summary of the 2017 thyroid radiofrequency ablation guideline and comparison with the 2012 guideline

Ultrasonography. 2019 Apr;38(2):125-134. doi: 10.14366/usg.18044. Epub 2018 Sep 27.

Authors

Ji-Hoon Kim¹, Jung Hwan Baek², Hyun Kyung Lim³, Dong Gyu Na^{4

5}

Affiliations

¹ Department of Radiology, Seoul National University Hospital, Seoul, Korea.
² Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
³ Department of Radiology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
⁴ Department of Radiology, GangNeung Asan Hospital, Gangneung, Korea.
⁵ Department of Radiology, Human Medical Imaging and Intervention Center, Seoul, Korea.

Abstract

Radiofrequency ablation (RFA) is a new, minimally invasive modality that serves as an alternative to surgery in patients with thyroid tumors. The Task Force Committee of the Korean Society of Thyroid Radiology developed recommendations for the optimal use of RFA for thyroid tumors in 2012 and revised them in 2017. Herein, we review and summarize the 2017 thyroid RFA guideline and compare it with the 2012 thyroid RFA guideline.

Keywords: Ethanol ablation; Radiofrequency ablation; Thyroid; Thyroid neoplasms; Thyroid nodule; Ultrasonography.